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ABSTRACT
Objective To pilot test the proposed DiaPROM trial 
components and address uncertainties associated with 
conducting a full- scale randomised controlled trial (RCT) to 
evaluate whether such a trial is feasible.
Design Two- arm pilot RCT.
Participants Adults aged ≥18–39 years, with minimum 
1 year type 1 diabetes duration, attending outpatient 
follow- up. Exclusion criteria were pregnancy, severe 
cognitive, somatic or psychiatric conditions and impaired 
vision.
Randomisation and intervention All participants 
completed electronic Patient- Reported Outcome Measures 
(PROMs) prior to the annual diabetes consultation. Using 
computer- generated block- randomisation without blinding, 
we assigned participants in a 1:1 ratio stratified by sex 
to receive standard care or an intervention. Physicians 
reviewed diabetes distress scores (Problem Areas In 
Diabetes scale) and referred individuals with scores 
≥30 or single item(s) ≥3 to minimum two diabetes nurse 
consultations where reported problems were reviewed and 
discussed.
Outcomes Recruitment and retention rates; participants 
perceptions about intervention components. Variance and 
estimated between- group differences in follow- up scores 
(Diabetes Distress Scale (DDS), WHO 5- Well- being Index, 
Perceived Competence for Diabetes Scale and glycaemic 
control) and DDS correlation with baseline scores, to assist 
sample size calculations.
Results We randomised 80 participants to the control 
or intervention arm (one participant was later excluded). 
23/39 intervention arm participants qualified for additional 
consultations and 17 attended. 67/79 attended the 
12- month follow- up (15.2% attrition); 5/17 referred to 
additional consultations were lost to follow- up (29.4% 
attrition). Participants reported PROMs as relevant (84.6%) 
and acceptable (97.4%) but rated the usefulness of 
consultations as moderate to low. Baseline mean±SD DDS 
score was 2.1±0.69; DDS SD was 0.71 (95% CI: 0.60 
to 0.86) at follow- up; correlation between baseline and 
follow- up DDS scores was 0.8 (95% CI: 0.7 to 0.9).
Conclusions The pilot trial revealed need for intervention 
modifications ahead of a full- scale trial to evaluate use of 
PROMs in diabetes consultations. Specifically, participant 
acceptability and intervention implementation need further 
investigation.
BACKGROUND
Type 1 diabetes (T1D) is a chronic, auto-
immune disease which requires lifelong 
insulin therapy.1 Self- management of T1D, 
the cornerstone of diabetes care, can be 
described as a 24- hour activity with a constant 
need to make complex medical decisions 
and perform challenging diabetes self- 
management tasks.2 During emerging and 
young adulthood, multiple transitions and 
developmental stressors can trigger addi-
tional self- management difficulties.3 Despite 
advancements in glucose monitoring, insulin 
therapy and insulin delivery devices, the 
burden of living with T1D remains a signif-
icant challenge.4 5 Only 20%–30% of young 
adults with T1D achieve recommended 
glycaemic treatment goals.6–9 Poor general 
Strengths and limitations of this study
 ► This pilot trial systematically addressed procedural 
uncertainties associated with designing a large- 
scale randomised controlled trial.
 ► The pilot trial allowed us to test the feasibility of 
Patient- Reported Outcome Measures as dialogue 
support tools in clinical diabetes consultations.
 ► Well- known, validated tools for measuring the pri-
mary and secondary outcomes facilitated compar-
ison with other studies.
 ► One of the limitations was that we did not specifi-
cally predefine retention and attrition criteria for trial 
progression.
 ► Logistical challenges concerning cancelled appoint-
ments and non- attendance contributed to difficulties 
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well- being and emotional distress are known barriers for 
self- management, and performing behavioural adjust-
ments necessary to promote effective self- management 
can be challenging.10 In addition, individual efforts to 
achieve beneficial outcomes may not produce desired 
results.11 Diabetes guidelines recommend routine assess-
ment of psychological, emotional and psychosocial 
factors that impact personal ability to self- manage, like 
diabetes distress.2 12 Nevertheless, recent studies indicate 
that biomedical outcomes receive disproportionate atten-
tion in routine follow- up compared with what people with 
diabetes find important, such as psychosocial aspects.13 14
The construct diabetes distress refers to specific nega-
tive emotional experiences related to the challenges of 
living with and managing diabetes and the risk of acute 
and long- term complications.10 15 16 Diabetes distress is 
regarded as an expected reaction first of all impacting 
on well- being.17 In T1D studies, regimen distress, fear of 
hypoglycaemia and complications, feeling overwhelmed 
and worrying about the future is most commonly 
reported.18 Furthermore, diabetes distress is more prev-
alent among younger than older adults3 and associated 
with problematic self- management behaviours related to 
insulin treatment, glucose monitoring and unsatisfactory 
glycaemic control.19–22 Regimen distress appears to drive 
these associations.18 However, distress may also occur in 
individuals who reach recommended treatment goals.23 
Left untreated, mild cases may develop into severe and 
even chronic distress.24 In addition, diabetes distress is 
found to be a risk factor for symptoms of depression.25 
This highlights the importance of addressing diabetes 
distress in routine diabetes care.17 26
Patient- reported outcome measures (PROMs) are 
self- report questionnaires measuring patients’ subjec-
tive appraisal of a condition, treatment or other health- 
related outcomes.27 In clinical consultations, PROMs can 
be used to increase attention to individual needs, values 
and preferences. By using PROMs regularly, healthcare 
providers can screen for self- reported health outcomes, 
track progress over time and enhance communication 
with patients.27–30 Prior to implementation in clinical care 
settings, studies are needed to evaluate the feasibility, 
acceptability and effect of using PROMs in routine consul-
tations. We used the Medical Research Council’s (MRC) 
framework for developing and evaluating complex 
interventions for guidance.31 32 Accordingly, we devel-
oped the Diabetes Patient- Reported Outcome Measures 
(DiaPROM) trial ( ClinicalTrials. gov ID: NCT03471104). 
The overarching aim was to develop, test and evaluate 
a structured empowerment- based intervention using 
PROMs regarding diabetes distress as dialogue support in 
diabetes consultations among adults with T1D.33 Further-
more, we hypothesise that the DiaPROM intervention will 
reduce diabetes distress and improve overall well- being, 
perceived competence for diabetes management and 
glycaemic control. First, we conducted a feasibility study 
to test the technical and practical feasibility and accept-
ability of capturing PROMs on a touchscreen computer 
in an outpatient clinic.34 Then, we conducted the present 
pilot trial to test all the components of an upcoming fully 
powered randomised controlled trial (RCT), to deter-
mine if such a trial is feasible and appropriate. Here we 
report the results of the pilot trial using the Consolidated 
Standards of Reporting Trials 2010 statement: extension 
to randomised pilot and feasibility trials.35 Findings from 




To pilot test the proposed DiaPROM trial components 
and address uncertainties associated with conducting 
a full- scale RCT in order to evaluate whether the trial 
methods and the intervention are feasible. The pilot trial 
objectives were thus to:
1. Evaluate the recruitment procedures, randomisation 
procedure and attrition rates.
2. Evaluate the acceptability, appropriateness and imple-
mentation of the intervention components.
3. Estimate variance and between- group differences in 
participant outcomes (diabetes distress; general well- 
being; perceived diabetes competence and glycaemic 
control) following intervention or standard care, and 
correlation between participants’ diabetes distress 
scores at baseline and 12 months, in order to assist fu-
ture sample size calculations.
Design
The study was designed as a single- centre two- arm pilot 
RCT.
Setting and participants
In Norway, people with T1D are followed up at hospital 
clinics. We conducted the pilot trial at a university hospital 
endocrinology outpatient clinic where approximately 
80% of the patients with diabetes have T1D. Eligible 
participants aged ≥18–39 years with T1D duration for at 
least 1 year were identified using the clinic’s attendance 
list. We sent invitation letters with consent forms by mail 
10–14 days prior to the patients’ annual diabetes consul-
tations. Informed by pilot trial sample size guidance and 
the diabetes distress proportions documented in our 
feasibility study,34 38 we aimed to recruit 80 participants, 
40 in each arm. Using information from the electronic 
patient records (EPR), we applied the following exclu-
sion criteria: ongoing pregnancy, severe cognitive defi-
ciency, severe somatic comorbidity (eg, end- stage renal 
disease, severe heart failure, severe cancer), major psychi-
atric diagnosis (eg, severe depression or bipolar disorder, 
schizophrenia) and/or impaired vision.
Pilot trial intervention
We have described the intervention in detail in our 
protocol paper.33 Briefly, DIPS, eHealth systems supplier to 




pril 14, 2021 at H










pen: first published as 10.1136/bm





3Hernar I, et al. BMJ Open 2021;11:e042353. doi:10.1136/bmjopen-2020-042353
Open access
for capturing and transferring electronic PROMs to the 
diabetes- specific EPR.39 We asked all participants to arrive 
15 min early to complete PROMs on a stationary touch-
screen computer located in the outpatient clinic’s waiting 
area prior to two annual diabetes consultations (baseline 
and 12 months). While completing PROMs, participants 
received an individual four- character code which was 
used to download the PROMs to the EPR. The length of 
the annual consultations was increased from 30 to 45 min. 
Furthermore, we used the 20- item Problem Areas In Diabetes 
(PAID) scale to assess diabetes distress.40–42 PAID items are 
rated on a 5- point Likert- like scale (0, ‘not a problem’ 
to 4, ‘serious problem’), and an overall diabetes distress 
score of 0–100 is calculated, with higher scores indicating 
greater distress. A score ≥40 suggests serious diabetes 
distress.10 41 The PAID is widely used, and the Norwegian 
version is available in the diabetes- specific EPR.43
We developed a manual to guide the physicians to down-
load PROMs and review and discuss PAID scores with 
intervention arm participants, and to identify moderate 
and serious distress, specifically PAID total score ≥30 or 
at least one item scored 3 or 4. Next, the physicians were 
to offer individuals with such scores a minimum of two 
30- min diabetes specialist nurse consultations; the first 
within 4 weeks after randomisation and the second within 
a further 3 months. We also developed a communica-
tion manual where we guided the nurses to review base-
line PAID and discuss reported problem areas with the 
participants using person- centred, empowerment- based 
communication skills; ‘asking open questions’, ‘active 
listening’, ‘responding’, ‘summing up’ and ‘agreeing on 
goals and actions to take’. In addition, we requested the 
nurses to record problem areas discussed, goals, action 
strategies and plans in the EPR. In the second consulta-
tions, we asked the nurses and participants to discuss the 
problem areas, goals and actions and to decide whether 
to continue with consultations (optional number) until 
the next annual physician consultation. Intervention arm 
participants with lower PAID scores received follow- up 
according to standard clinical protocols after the brief 
review of their PAID scores with the physicians. Control 
arm participants, whose scores were inaccessible to the 
clinicians in the EPR, received ‘care as usual’.
Outcomes
Recruitment
We recorded the number of individuals invited, number 
of people attending consultations and number of people 
who consented to participate in the pilot trial. At base-
line, we observed if eligible participants started the PROM 
sessions by themselves and provided a friendly reminder 
or assistance to those who did not. At 12 months, we 
performed similar observations and guidance.
Sample characteristics
Sociodemographic and diabetes- related information 
was gathered from the participants’ EPR: age, sex, 
ethnic origin, diabetes duration, diabetes long- term 
complications, comorbidities, body mass index, glyco-
sylated haemoglobin (Haemoglobin A1c (HbA1c)) level, 
number of self- reported symptomatic hypoglycaemic 
events in the previous month, history of hypoglycaemia 
requiring assistance and hospitalisation due to ketoac-
idosis and insulin injection device. We also obtained 
self- report data on current type of glucose monitoring 
device, daily glucose measurement count, first language, 
educational level, cohabitation status and work affilia-
tion. In addition, we received ethical approval to record 
age, sex and HbA1c of eligible participants who declined 
participation.
Primary outcome measure
To avoid using the same questionnaire for diabetes distress 
assessment as an element of the intervention and as an 
outcome measure, we chose the Diabetes Distress Scale (DDS) 
as our primary outcome.43 The 17- item DDS measures 
diabetes- specific problems rated on a 6- point Likert- like 
scale (1, ‘no problem’ to 6, ‘serious problem’).44 The scale 
yields an overall diabetes distress score and four subscales: 
emotional burden (five items; eg, ‘Feeling that diabetes 
controls my life’), physician- related distress (four items; 
eg, ‘Feeling that my doctor doesn't take my concerns seri-
ously enough’), regimen- related distress (five items; eg, 
‘Feeling that I am not testing my blood sugars frequently 
enough’) and diabetes- related interpersonal distress 
(three items; eg, ‘Feeling that friends or family are not 
supportive enough of self- care efforts’). Item scores are 
averaged to form a total and subscale scores from 1 to 6, 
with higher values indicating greater distress.45 Scores are 
then categorised as little or no distress (<2.0), moderate 
distress (2.0–2.9) and high distress (≥3.0). Moderate and 
high distress is considered clinically relevant.45
Secondary outcomes measures
We used the WHO 5- Well- being Index (WHO-5) 5- item 
measure of current general well- being.46 Items are scored 
on a 6- point Likert- like scale (0, ‘at no time’ to 5, ‘all the 
time’). A 0–100 score is calculated and scores <50 suggest 
impaired well- being, while ≤28 indicate likely depres-
sion.46 47 A 10- point change is considered clinically rele-
vant.46 The measure is reported to be psychometrically 
sound, acceptable and suitable for diabetes outpatient 
settings.48–50 The 4- item Perceived Competence for Diabetes 
Scale (PCDS) assesses the degree to which people with 
diabetes feel they can manage daily aspects of diabetes 
care (1, ‘strongly disagree’ to 7, ‘strongly agree’).51 Item 
scores are averaged to form a score. Finally, we obtained 
information about glycaemic control from routinely 
performed blood samples measuring HbA1c (mmol/mol) 
recorded in the EPR.
Experiences with the pilot trial intervention
After each annual consultation, participants were asked 
to complete a paper questionnaire, which included the 
DDS (primary outcome measure) and questions about 
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components. We asked all participants PROMs accept-
ability questions (five response options from ‘not at 
all’ to ‘very large degree’): relevance, number of items 
and willingness for annual completion. In addition, we 
asked about preferred completion method (electronic 
or paper). Intervention arm participants were also asked 
about PAID use and consultation usefulness. Finally, we 
reviewed the nurses’ EPR notes for intervention arm 
participants referred to additional follow- up, to evaluate 
intervention consultation fidelity (per- protocol).
Randomisation
We randomised participants in a 1:1 ratio to an inter-
vention or control arm using computer- generated 
block- randomisation at the patient level, developed and 
administered by DIPS.39 The computerised allocation 
took place when the physicians downloaded PROMs to 
the EPR. Group allocation information appeared on the 
computer screen, and the physicians told the partici-
pants. Furthermore, we stratified by sex to ensure equal 
numbers (20) of male and female participants in each 
arm. Due to the nature of the intervention, blinding of 
group allocation to participants, healthcare providers 
and research personnel was not possible.
Analyses
All analyses were carried out using Stata SE 16 for 
Windows.52 At each timepoint, we estimated means, 
SD and 95% CI of SDs of outcome measures for both 
groups. To examine within and between- group variation 
of paired differences in outcome measures from base-
line to 12- month follow- up, we estimated means and SDs, 
and means and 95% CIs, respectively. Using Spearman’s 
correlation coefficient, we estimated correlation with 
95% CI between participants’ primary outcome measure 
scores at baseline and 12 months. The primary outcome 
measure SD, 95% CI of SD and correlation coefficient was 
used to assist in full trial sample size calculations. In all 
analyses, we computed missing items using person- mean 
substitution if at least 50% of the items per scale were 
completed.53 54
Patient and public involvement
In the protocol paper,33 we have provided a detailed 
description of health service user involvement based on 
the Guidance for Reporting Involvement of Patients and the 
Public 2 (GRIPP2) short form.55
RESULTS
Recruitment, randomisation, sample characteristics, and 
retention
Between 15 January and 7 May 2018, we assessed 149 
patients with T1D for eligibility and randomised 80 
participants, 40 (50%) to each trial arm (figure 1). The 
randomisation procedure yielded two groups with equal 
distribution of men and women. Baseline characteris-
tics for the total sample and trial arms are presented in 
table 1. Compared with the included participants, the 
22 who declined had longer diabetes duration (13.7±7.0 
years (95% CI: 12.2 to 15.3) vs 18.6±10.2 years (95% CI: 
14.1 to 23.1)), while there were no differences in gender 
distribution, age or HbA1c level. Furthermore, 24/40 
(60.0%) intervention arm participants qualified for addi-
tional nurse follow- up (figure 1). One participant was 
later excluded due to newly discovered language prob-
lems. In total, 17/23 (73.9%) were referred and attended 
1–5 consultations (mean±SD 2.2±1.1); 12/17 (70.6%) 
attended the per- protocol minimum. After reviewing the 
nurses’ EPR notes, we registered that 28/38 consultations 
were performed according to the protocol, while 10/38 
focused on other aspects than diabetes distress assessed 
by the PAID. Therefore, a mean of 1.65 (0–2) interven-
tion consultations was conducted, and 9/17 received 
per- protocol follow- up of minimum two sessions. The 
12- month follow- up was performed from 5 December 
2018 to 17 June 2019. Twelve participants were lost to 
follow- up (overall attrition rate 15.2%; intervention arm: 
8 (20.5%); control arm: 4 (10%)), but none withdrew 
consent (figure 1). Furthermore, 5/17 referred to addi-
tional nurse consultations were lost to follow- up (attrition 
rate 29.4%).
Acceptability, appropriateness and implementation of the 
intervention components
At baseline, 21/79 (26.6%) participants located the 
touchscreen computer without guidance, 43 (54.4%) 
confirmed they had read the written study information. 
At 12 months, five participants completed PROMs on 
paper; four because of a defective touchscreen and one 
asked for a telephone consultation. Of the remaining 62 
participants, we had to remind 30 (48.4%) to complete 
PROMs. Furthermore, 2/17 participants referred to addi-
tional nurse follow- up delayed the first consultation for 
4–6 months. The remaining 15/17 were offered the first 
consultation within 27.0±4.8 (19–35) days after randomis-
ation. However, due to five participants postponing at least 
once, the consultations were conducted after 42.5±27.7 
(22–123) days. The second appointments (n=15) were 
offered after 85.5±30.6 (20–133) days and attended by 12 
participants after 100.8±35.3 (20–153) days.
Total WHO-5, PAID and PCDS completeness was 99.4% 
at baseline and 99.2% at 12 months. When asked about 
preferred method for completing PROMs in the future, 
two (2.6%) individuals chose paper- completion, whereas 
42 (54.5%) opted for in- clinic computerised PROMs 
and 33 (42.9%) favoured home- based web- completion 
(online supplemental figure 1). Seventy- five (97.4%) 
reported that number of items were acceptable to a large 
or very large degree, 72 (92.3%) found the items relevant 
and 66 (84.6%) were willing to complete PROMs annu-
ally (online supplemental figure 1).
Among intervention arm participants, 23/39 (59.0%) 
and 13/31 (41.9%) reported PAID items scored ≥3 and/
or a total score ≥30 (moderate to high distress) at baseline 
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The control arm participants’ corresponding proportions 
were 19/40 (47.5%) and 20/36 (55.6%). Thirty (76.9%) 
intervention group participants reported that the PAID 
results were discussed at baseline, of which 15 (38.5%) 
found it useful to a large or very large degree and 10 
(25.6%) to some degree. At 12 months, 20/24 (83.3%) 
reported that PAID was discussed and 11 (45.8%) found it 
useful to a large or very large degree. Only 10/17 referred 
to additional follow- up completed all items about PAID 
use; five found the discussions useful; four reported to 
have benefitted to a large degree, whereas three had not 
benefitted at all. In total, 17/53 (32.1%) participants 
stated that completing PROMs had to some degree led 
to discussions related to diabetes- related challenges 
which would not otherwise have been discussed (similar 
in both trial arms). Furthermore, 14 (26.4%) reported 
that completing PROMs had been a positive experience, 
while 24/53 (45.2%) found it somewhat positive (similar 
in both trial arms).
Outcome measures
In total, 67/79 (84.8%) participants responded to all 
DDS items at baseline and 58/67 (86.6%) at 12 months 
(online supplemental table 2). Mean scores and SDs of 
the outcome measures at baseline and follow- up for each 
trial arm are reported in tables 2 and 3. At follow- up, 
the sample’s SD of DDS score was 0.71 (95% CI: 0.60 to 
0.86) (table 2). From baseline to follow- up, we observed a 
Figure 1 The DiaPROM pilot trial’s consolidated standards of reporting trials flow diagram.  
(CONSORT, Consolidated Standards of Reporting Trials; DiaPROM, Diabetes Patient- Reported Outcome Measures; DDS, 
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reduction in DDS overall score by an average of 0.25 (SD: 
0.42) in the intervention arm but no apparent reduction 
in the control arm (0.00, SD: 0.47). The intervention 
arm’s DDS subscale scores were all improved (−0.14 to 
−0.39, SDs: 0.66 to 0.86), while the control arm’s changes 
in subscales scores ranged from −0.07 to 0.09 (SDs: 0.54 
to 0.82). For other outcome variables (WHO-5, PCDS 
and HbA1c), only small changes were seen (table 3). The 
correlation coefficient between baseline and follow- up 
DDS scores was 0.8 (95% CI: 0.7 to 0.9) (online supple-
mental table 3).
In addition, 18/33 (54.5%) and 11/26 (42.3%) inter-
vention arm participants reported moderate to high 
distress measured by the DDS overall score at baseline 
Table 1 Baseline sociodemographic and clinical characteristics of the DiaPROM pilot trial participants with type 1 diabetes 
aged 18–40 years (n=79)
All Groups
  n=79 Intervention, n=39 Control, n=40
Gender, women 40 (50.6) 20 (50.6) 20 (50.0)
Age, years 27.2±5.0 27.1±4.7 27.3±5.3
European origin 79 (100.0) 39 (100.0) 40 (100.0)
Norwegian first language 74 (93.7) 36 (92.3) 38 (95.0)
Living alone 17 (21.5) 4 (10.3) 13 (32.5)
University/college education 37 (46.8) 21 (53.9) 16 (40.0)
Work affiliation
  Full- time work 36 (45.6) 18 (46.2) 18 (45.0)
  Part- time work 5 (6.3) 0 (0.0) 5 (12.5)
  Student 25 (31.7) 15 (38.5) 10 (25.0)
  Other 13 (16.4) 6 (15.3) 7 (17.5)
Diabetes duration, years 13.7±7.0 13.6±6.4 13.9±7.6
Long- term complication(s) 16 (20.3) 4 (10.3) 12 (30.0)
  Retinopathy* 15 (19.0) 4 (10.3) 11 (27.5)
  Nephropathy 1 (1.3) 0 (0.0) 1 (2.5)
Comorbidities/other autoimmune diseases
  Thyroid disease 5 (6.3) 2 (5.1) 3 (7.5)
  Coeliac disease 8 (10.1) 4 (10.2) 4 (10.0)
HbA1c (mmol/mol)† 65.4±14.5 64.8±13.2 66.0±15.8
HbA1c (%) 8.1±1.3 8.1±1.2 8.2±1.4
HbA1c ≤53 mmol/mol (≤7.0%)‡ 15 (19.0) 7 (18.0) 8 (20.0)
Body Mass Index (kg/m2) 24.6±5.6 24.2±7.1 25.0±3.6
Symptomatic hypos last month 9.8±10.5 11.4±12.6 8.1±7.5
Severe hypoglycaemic event ever§ 34 (43.0) 18 (46.1) 16 (40.0)
Ketoacidosis (ever hospitalised) 17 (21.5) 7 (17.9) 10 (25.0)
Insulin pump 38 (48.1) 20 (51.3) 18 (45.0)
Continuous glucose monitoring (CGM) 22 (27.9) 11 (28.2) 11 (27.5)
Self- blood glucose monitoring (SBGM) 53 (67.1) 27 (69.2) 26 (65.0)
Flash glucose monitoring (FGM) 2 (2.5) 1 (2.5) 1 (2.5)
  Daily SBGM/FGM¶ 47 (85.5) 25 (89.3) 22 (81.5)
  Weekly count SBGM/FGM 32.8±22.9 39.4±25.3 26.7±18.9
Data are shown as n (%) (of patients with valid values) or mean±SD.
*Any degree of retinopathy
†Haemoglobin A1c.
‡HbA1c target achieved.
§At least one severe hypoglycaemic event with need of assistance (yes).
¶Total n based on participants using SBGM or FGM.
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and follow- up, respectively (online supplemental table 4). 
Corresponding proportions for control arm participants 
were 15/39 (38.5%) and 17/34 (50.0%). Regarding 
DDS subscales, the percentage of participants reporting 
moderate to high emotional burden and regimen- 
related distress was persistent at ~60%, across groups and 
timepoints.
DISCUSSION
In this randomised controlled pilot trial, we found that it 
was feasible to recruit and randomise young adults with 
T1D attending routine diabetes consultations to a trial 
using PAID and communication techniques as dialogue 
support tools. The participants were positive towards 
completing PROMs. Furthermore, we were able to retain 
67/79 (84.8%) participants at 12 months. However, we 
identified implementation challenges related to the inter-
vention consultations, and 5/17 (29.4%) participants 
referred to additional consultations were lost to follow- up 
at 12 months.
Strengths and limitations
The pilot trial’s key strengths were that it systematically 
addressed uncertainties associated with designing a large- 
scale RCT. Moreover, well- known, validated tools for 
measuring primary and secondary outcomes allowed for 
comparison with other studies. The results inform tech-
nical and practical issues of conducting a full- scale trial. 
Similar to our feasibility study,34 findings suggest that 
completing electronic PROMs was generally accepted and 
technically feasible. We were able to recruit and randomise 
80 participants over 15 weeks. However, one fundamental 
limitation was that the 12- month follow- up lasted nearly 
twice as long (28 weeks), mainly caused by cancelled 
appointments, non- attendance and loss to follow- up. 
Another limitation was not having predefined criteria for 
retention and attrition progression rates. However, this is 
not yet common.56 Furthermore, complete follow- up was 
not achieved, and attrition differed by trial arm: 10% in 
the control arm, 20% in the intervention arm and 29% 
among those who were referred to additional follow- up. 
Systematic differences between completers and drop- outs 
may have introduced attrition bias.57 However, clinic non- 
attendance is not uncommon among young adults with 
T1D and has been linked to difficulties communicating 
with the services, conflicting schedules, low perceived 
value of attendance and challenges with developing rela-
tionships.58 59 The retention, implementation and accept-
ability issues are further explored in qualitative interviews. 
In summary, these issues will impact power calculations 
by increasing the target sample needed, in addition to 
affecting intervention implementation and the duration 
of a full- scale RCT.
Generalisability and transferability to other settings and 
populations may be limited due to our use of electronic 
technologies for completing PROMs, our choice of only 
including young adults with T1D, and that the Norwegian 
health insurance system differs from other countries. 
Finally, although PAID scores were not accessible in 
the control arm participants’ EPRs, we cannot rule out 
contamination. Since all participants completed PROMs 
in the same manner, control arm participants’ consulta-
tions may have been influenced by individual responses 
and thoughts about the questionnaires. Moreover, 
consulting styles within a service probably differs between 
clinicians. For ethical reasons, we could not instruct the 
physicians to avoid discussing diabetes distress in the 
control arm if participants requested it.
Implications and future research
Using current pilot trial data and a conservative DDS SD 
estimate to calculate the minimal clinically important 
difference (0.5 x SD),60 and assuming that SD (0.71) is 
equal for each trial arm in a full- scale, single- site RCT, we 
estimate at least 107 participants will be required per arm 
to provide 90% power based on a two- sided 5% signifi-
cance level. The calculation was based on the formula of 
a two- sample t- test for difference post- intervention and 
allowed for 25% attrition.
Since 10% of the participants did not complete the 
paper- based measures, and there was considerably 
more missing DDS items than other PROM items, we 
will strive for capturing all future data electronically. 
Furthermore, only a minority of participants approached 
the touchscreen computer by themselves. Therefore, 
we will continue with in- clinic guidance and e- mail or 
SMS reminders to support data collection. A web- based 
PROMs platform, recently available in Norway, will 
possibly enable more complete data collections in future 
studies. Moreover, we observed that 36 (45.6%) partici-
pants had not read the study information prior to coming 
to the clinic but still consented. The drop- out rates and 
other findings suggest that consultations were not consid-
ered useful, adequate or appropriate by the participants. 
This could in part be explained by protocol inflexibility 
and/or the waiting time between PROMs completion and 
additional consultations. In addition, we may not have 
provided sufficient detailed information about the nature 
of the intervention components, especially the additional 
follow- up. Also, this key intervention component may 
not have fitted the participants’ personal beliefs, pref-
erences, capabilities and/or life circumstances.61 We 
may also have underestimated the contribution of the 
baseline review of scores and discussions between inter-
vention arm participants and physicians. Furthermore, 
our criteria for offering additional follow- up may have 
led to overinclusion of cases but we must also consider 
barriers to clinic attendance and dissatisfaction with the 
follow- up.14 58 Another aspect which requires consider-
ation, is that simply answering questions for assessment 
purposes, such as PROMs, may affect research partici-
pants by stimulating new thinking about problem areas or 
behaviours, which then may lead to action- taking.62 This 
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Diabetes distress scores were similar to previous 
studies.20 21 63 Approximately half of the participants 
reported moderate to serious distress, which supports 
statements that diabetes distress is common and worthy 
of individual attention in diabetes care.4 12 15 Although 
the pilot trial was not powered for inferential statements, 
the observed between- group differences in DDS scores 
suggest promising effects of assessing and addressing 
diabetes distress. Compared with lack of assessment and 
follow- up, education- based or emotion- focused interven-
tions targeting diabetes distress in adults with T1D have 
been found clinically effective.24 64 65 In the pilot trial, 
we focused on real- life clinical consultations. Hence, the 
clinicians meet individuals with different needs which 
may entail applying either education- based or emotion- 
focused interventions or both, depending on individual 
diabetes distress foci, discussions with each individual 
and clinical experience. Personalising diabetes care by 
addressing diabetes distress systematically, may increase 
healthcare providers’ attentiveness towards the individual 
experiences of living with diabetes.
Implementation fidelity and difficulties in delivering 
the intervention as designed appeared challenging for 
the clinic. One aspect was providing the consultations 
within the specified timeframe. Recommendations of 
2- week to 1- month intervals between consultations23 66 
may be difficult to achieve within regular working hours 
unless telephone or digital communication are used.67 
The observed lack of intervention fidelity, for example, 
not reviewing the PAID during annual consultations, 
may be partly explained by low sense of project owner-
ship from the clinicians. This highlights the importance 
of organisational incentives, management facilitation of 
new intervention initiatives and possibly cultural aspects 
in this setting. Our efforts to encourage intervention 
fidelity by providing information, developing manuals 
and arranging meetings and training for the clinicians 
may not have been sufficient. Consequently, we must seek 
to further identify key contextual, organisational and 
behavioural factors and mechanisms of impact. The pilot 
trial results show that we must involve health service users 
and clinicians in further development of the intervention 
and undertake more feasibility work with process evalua-
tions to inform the design of a full- scale trial.68
CONCLUSIONS
Results from this randomised controlled pilot trial show 
that it is feasible to recruit and randomise young adults 
with T1D attending an outpatient clinic to a study using 
electronically captured PROMs to assess diabetes distress. 
However, the intervention was not provided as planned. 
Low perceived usefulness and high attrition rate among 
intervention arm participants also suggest low accept-
ability or overinclusion. The pilot trial revealed problems 
with design and deliverability and highlighted the need 
for several intervention modifications before initiating 
a full- scale evaluation of using electronic PROMs in 
diabetes consultations.
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